Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis
Authors' conclusion
GLP-1RAs demonstrate efficacy and safety in T2DM patients with overweight/obesity, with certain advantages over other drugs. However, due to limitations in the number and quality of included studies, conclusions should be interpreted with caution.
Study context
- Population
- T2DM patients with overweight/obesity treated with GLP-1 RAs; Randomized controlled trials (RCTs) searched up to December 20, 2024
- Participants
- 15,126 patients41 RCTs
- Comparison
- GLP-1 RAs vs placebo or another GLP-1 RA
- Outcome
- Glycaemic control and weight loss
Methodological detailsCINeMA evidence assessment
- CINeMA evidence assessment
Pooled result
As reported in the abstract
- Tirzepatide
- HbA1c −1.64 (CI −1.94 to −1.35)
- Tirzepatide
- fasting blood glucose −2.10 (CI −2.95 to −1.25)
- Tirzepatide
- weight −9.89 (CI −11.29 to −8.49)
- Tirzepatide
- BMI −3.85 (CI −4.71 to −2.99)
Further pooled results
- Clinical efficacy of GLP-1 RAs in lipid levels, blood pressure and pancreatic function was not widely observed
Safety
- Adverse reactions were significant with GLP-1 RAs, but overall acceptable
Original publication
Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis. Diabetes Res Clin Pract. Published 17 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →